Biomarin Pharmaceutical INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Vanguard Capital Management has reported a beneficial ownership of 5.25% in BioMarin Pharmaceutical Inc. as of March 31, 2026.
NASDAQ
SCHEDULE 13G/A: BlackRock Boosts BioMarin Stake to 9.1%
BlackRock, Inc. has reported a 9.1% beneficial ownership stake in BioMarin Pharmaceutical Inc., holding 17,560,751 common shares as of December 31, 2025.
NASDAQ
Viking Global Investors LP and its affiliates report a passive beneficial ownership of 4.3% in BioMarin Pharmaceutical Inc. common stock.
NASDAQ
Viking Global Investors LP and its affiliates, along with key executives, have disclosed a collective beneficial ownership of 6.4% in BioMarin Pharmaceutical Inc., totaling 12,288,611 shares.
NASDAQ
SCHEDULE: PRIMECAP Boosts BioMarin Stake to 8.24%
PRIMECAP MANAGEMENT CO/CA/ has increased its beneficial ownership in BioMarin Pharmaceutical Inc. to 8.24% of the common stock.
NASDAQ
SCHEDULE 13G/A: Capital Research Global Investors Discloses 4.8% Passive Stake in BioMarin Pharmaceutical Inc.
Capital Research Global Investors, a division of Capital Research and Management Company, has filed an amended Schedule 13G disclosing a 4.8% beneficial ownership stake in BioMarin Pharmaceutical Inc. as of March 31, 2025.
NASDAQ
SCHEDULE 13G/A: BlackRock Amends Stake in BioMarin Pharmaceutical, Reports 10.8% Beneficial Ownership
BlackRock, Inc. has filed an amended Schedule 13G, disclosing its beneficial ownership of 10.8% of BioMarin Pharmaceutical Inc.'s common stock as of March 31, 2025.
NASDAQ
Capital Research Global Investors has filed an amended Schedule 13G, reporting a 6.8% beneficial ownership stake in BioMarin Pharmaceutical Inc. as of December 31, 2024.